Cabaletta Bio (MEX:CABA) Stock Based Compensation: MXN385.54 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:CABA Cabaletta Bio Inc MEX:CABA
14 GF Score
Price MXN54.50
! 1 Warning Sign
View Full Analysis

What is Cabaletta Bio Stock Based Compensation?

Cabaletta Bio MEX:CABA 14 Stock Based Compensation is MXN385.54 Mil as of Mar. 2026. GuruFocus rates MEX:CABA with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Cabaletta Bio's Stock Based Compensation for the three months ended in Mar. 2026 was MXN94.78 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was MXN385.54 Mil.

Cabaletta Bio Stock Based Compensation Related Terms

Cabaletta Bio Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Cabaletta Bio's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cabaletta Bio Stock Based Compensation Chart

Cabaletta Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only 119.06 134.46 192.54 405.96 377.02

Cabaletta Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 105.59 107.42 106.67 76.67 94.78
MEX:CABA
14GF Score
Cabaletta Bio Inc MEX:CABA
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cabaletta Bio Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN385.54 Mil.

What does a Stock Based Compensation of MXN385.54 Mil mean?
Cabaletta Bio (MEX:CABA) has a Stock Based Compensation of MXN385.54 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Cabaletta Bio and its competitors.
Is Cabaletta Bio's Stock Based Compensation too high?
Cabaletta Bio's current Stock Based Compensation is MXN385.54 Mil. Overall, Cabaletta Bio has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Cabaletta Bio's Stock Based Compensation compare to RZLT and CCCC?
Cabaletta Bio's Stock Based Compensation of MXN385.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Cabaletta Bio and its competitors. Cabaletta Bio's current Stock Based Compensation is MXN385.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabaletta Bio stock overvalued right now?
Cabaletta Bio (MEX:CABA) has a current Stock Based Compensation of MXN385.54 Mil. The current Stock Based Compensation is MXN385.54 Mil. Cabaletta Bio's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Cabaletta Bio (MEX:CABA), the current Stock Based Compensation is MXN385.54 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cabaletta Bio Business Description

Other Exchanges CABA:USA
Address 2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
14GF Score

Get the complete analysis for MEX:CABA

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN54.50
Price